Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 396 JPY -1.38%
Market Cap: 2.5T JPY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Astellas Pharma Inc

Wall Street analysts forecast Astellas Pharma Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Astellas Pharma Inc is 1 793.74 JPY with a low forecast of 1 313 JPY and a high forecast of 2 310 JPY.

Lowest Forecast
Wall Street Target
1 313 JPY
6% Downside
Average Forecast
Wall Street Target
1 793.74 JPY
28% Upside
Highest Forecast
Wall Street Target
2 310 JPY
65% Upside
Lowest
Price Target
1 313 JPY
6% Downside
Average
Price Target
1 793.74 JPY
28% Upside
Highest
Price Target
2 310 JPY
65% Upside
Astellas Pharma Inc Competitors:
Price Targets
T
300119
Tianjin Ringpu Bio-Technology Co Ltd
21% Upside
INVA
Innoviva Inc
169% Upside
AARTIDRUGS
Aarti Drugs Ltd
2% Upside
C
DP3
Central Pharmaceutical JSC No3
21% Upside
T
300119
Tianjin Ringpu Bio-Technology Co Ltd
21% Upside
INVA
Innoviva Inc
169% Upside
AARTIDRUGS
Aarti Drugs Ltd
2% Upside
C
DP3
Central Pharmaceutical JSC No3
21% Upside
B
300558
Betta Pharmaceuticals Co Ltd
8% Downside
234080
JW Life Science Corp
32% Upside
IPN
Ipsen SA
23% Upside
LLY
Eli Lilly and Co
31% Upside

Revenue
Forecast

Revenue Estimate
Astellas Pharma Inc

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's revenue is 5%. The projected CAGR for the next 3 years is 0%.

5%
Past Growth
0%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Astellas Pharma Inc

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's operating income is -21%. The projected CAGR for the next 1 year is 998%.

-21%
Past Growth
998%
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Astellas Pharma Inc

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's net income is -17%. The projected CAGR for the next 2 years is 117%.

-17%
Past Growth
117%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Astellas Pharma Inc's stock price target?
Price Target
1 793.74 JPY

According to Wall Street analysts, the average 1-year price target for Astellas Pharma Inc is 1 793.74 JPY with a low forecast of 1 313 JPY and a high forecast of 2 310 JPY.

What is Astellas Pharma Inc's Revenue forecast?
Projected CAGR
0%

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's revenue is 5%. The projected CAGR for the next 3 years is 0%.

What is Astellas Pharma Inc's Operating Income forecast?
Projected CAGR
998%

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's operating income is -21%. The projected CAGR for the next 1 year is 998%.

What is Astellas Pharma Inc's Net Income forecast?
Projected CAGR
117%

For the last 8 years the compound annual growth rate for Astellas Pharma Inc's net income is -17%. The projected CAGR for the next 2 years is 117%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.